β‑hydroxyisovaleryl‑shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling Corrigendum in /10.3892/ol.2021.12456

Lu,Dan; Qian,Jing; Li,Wei; Feng,Qianqian; Pan,Shu; Zhang,Siquan

doi:10.3892/ol.2015.3769

β‑hydroxyisovaleryl‑shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling

Corrigendum in: /10.3892/ol.2021.12456

Authors:
- Dan Lu
- Jing Qian
- Wei Li
- Qianqian Feng
- Shu Pan
- Siquan Zhang
View Affiliations

Affiliations: Department of Gynecology & Obstetrics, College of Clinical Medicine, Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China
Published online on: September 30, 2015 https://doi.org/10.3892/ol.2015.3769
Pages: 3434-3442
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the inhibitory ability of β‑hydroxyisovaleryl‑shikonin (β‑HIVS) on the proliferation of human cervical cancer HeLa cells and to identify the mechanism of this effect. The HeLa cells were treated with β‑HIVS and the inhibition of cell growth was detected by an MTT assay. Flow cytometry was performed to analyze the apoptosis rate and cell cycle distribution of HeLa cells. Reverse transcription‑polymerase chain reaction and western blot analysis were used to examine the expression of the phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway proteins. The results revealed that β‑HIVS inhibited HeLa cell proliferation in a dose‑ and time‑dependent manner. With the administration of increasing concentrations of β‑HIVS, the apoptotic rate of HeLa cells was also increased. The cell cycle was slightly arrested at the S phase, with ~6% of cells in this phase, subsequent to treatment with 10 µM β‑HIVS. In addition, β‑HIVS markedly reduced the expression levels of PI3K, AKT, mTOR and 70‑kDa ribosomal protein S6 kinase in HeLa cells. β‑HIVS promoted cervical cancer cell apoptosis by inhibiting the PI3K/AKT/mTOR signaling pathway and suppressing downstream gene expression. The present study is expected to lead to the development of molecular targeted therapy for this signaling pathway as a novel method of cervical cancer treatment.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Roque DR, Wysham WZ and Soper JT: The surgical management of cervical cancer: An overview and literature review. Obstet Gynecol Surv. 69:426–441. 2014. View Article : Google Scholar : PubMed/NCBI
3	World Health Organization: Diagnosis and treatment of invasive cervical cancer. Comprehensive Cervical Cancer Control: A Guide to Essential Practice (2nd). (Geneva). World Health Organization. 153–175. 2014.
4	Mabuchi S, Kuroda H, Takahashi R and Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
5	Eskander RN and Tewari KS: Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol. 7:847–858. 2014. View Article : Google Scholar : PubMed/NCBI
6	Cho DC: Targeting the PI3K/Akt/mTOR pathway in malignancy: Rationale and clinical outlook. BioDrugs. 28:373–381. 2014. View Article : Google Scholar : PubMed/NCBI
7	Han Z, Wu K, Shen H, Li C, Han S, Hong L, Shi Y, Liu N, Guo C, Xue Y, et al: Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation. Dig Dis Sci. 53:1801–1810. 2008. View Article : Google Scholar : PubMed/NCBI
8	Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
9	Wu J, Chen C and Zhao KN: Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr Cancer Drug Targets. 13:143–156. 2013. View Article : Google Scholar : PubMed/NCBI
10	Tanaka S, Tajima M, Tsukada M and Tabata M: A comparative study on anti-inflammatory activities of the enantiomers, shikonin and alkannin. J Nat Prod. 49:466–469. 1986. View Article : Google Scholar : PubMed/NCBI
11	Mao X, Yu CR, Li WH and Li WX: Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res. 18:879–888. 2008. View Article : Google Scholar : PubMed/NCBI
12	Andújar I, Ríos JL, Giner RM and Recio MC: Pharmacological properties of shikonin - a review of literature since 2002. Planta Med. 79:1685–1697. 2013. View Article : Google Scholar : PubMed/NCBI
13	Andújar I, Recio MC, Giner RM and Ríos JL: Traditional chinese medicine remedy to jury: The pharmacological basis for the use of shikonin as an anticancer therapy. Curr Med Chem. 20:2892–2898. 2013. View Article : Google Scholar : PubMed/NCBI
14	Lu JJ, Bao JL, Wu GS, Xu WS, Huang MQ, Chen XP and Wang YT: Quinones derived from plant secondary metabolites as anti-cancer agents. Anticancer Agents Med Chem. 133:456–463. 2013. View Article : Google Scholar
15	Wang R, Yin R, Zhou W, Xu D and Li S: Shikonin and its derivatives: A patent review. Expert Opin Ther Pat. 22:977–997. 2012. View Article : Google Scholar : PubMed/NCBI
16	Rajasekar S, da Park J, Park C, Park S, Park YH, Kim ST, Choi YH and Choi YW: In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma. J Ethnopharmacol. 144:335–345. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yuan TL and Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
18	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
19	Martelli AM, Evangelisti C, Chiarini F and McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 1:89–103. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
21	Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A and McCubrey JA: The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta. 1803:991–1002. 2010. View Article : Google Scholar : PubMed/NCBI
22	Aimbetov R, Chen CH, Bulgakova O, Abetov D, Bissenbaev AK, Bersimbaev RI and Sarbassov DD: Integrity of mTORC2 is dependent on the rictor Gly-934 site. Oncogene. 31:2115–2120. 2012. View Article : Google Scholar : PubMed/NCBI
23	Huang S and Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 3:371–377. 2003. View Article : Google Scholar : PubMed/NCBI
24	Xu G, Zhang W, Bertram P, Zheng XF and McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 24:893–900. 2004.PubMed/NCBI
25	Welker ME and Kulik G: Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors. Bioorg Med Chem. 21:4063–4091. 2013. View Article : Google Scholar : PubMed/NCBI
26	Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X and Jiang BH: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 287:C281–C291. 2004. View Article : Google Scholar : PubMed/NCBI
27	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
28	Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 109:107–114. 2008. View Article : Google Scholar : PubMed/NCBI
29	Rao Z, Liu X, Zhou W, Yi J and Li SS: Synthesis and antitumour activity of β-hydroxyisovalerylshikonin analogues. Eur J Med Chem. 46:3934–3941. 2011. View Article : Google Scholar : PubMed/NCBI
30	Hashimoto S, Xu M, Masuda Y, Aiuchi T, Nakajo S, Cao J, Miyakoshi M, Ida Y, Nakaya K and Hashimoto S: Beta-hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL-60 cells through a mechanism different from those of Fas and etoposide. J Biochem. 125:17–23. 1999. View Article : Google Scholar : PubMed/NCBI
31	Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Anti-neoplastic effect of β-hydroxyisovalerylshikonin on a human choriocarcinoma cell line. Mol Med Rep. 3:515–518. 2010. View Article : Google Scholar : PubMed/NCBI
32	Nakaya K and Miyasaka T: A shikonin derivative beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs. 14:683–693. 2003. View Article : Google Scholar : PubMed/NCBI
33	Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, Shibuya M, Yamori T and Nakaya K: Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res. 93:944–951. 2002. View Article : Google Scholar : PubMed/NCBI
34	Kajimoto S, Horie M, Manabe H, Masuda Y, Shibayama-Imazu T, Nakajo S, Gong XF, Obama T, Itabe H and Nakaya K: A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity. Biochim Biophys Acta. 1782:41–50. 2008. View Article : Google Scholar : PubMed/NCBI
35	Komi Y, Suzuki Y, Shimamura M, Kajimoto S, Nakajo S, Masuda M, Shibuya M, Itabe H, Shimokado K, Oettgen P, et al: Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin. Cancer Sci. 100:269–277. 2009. View Article : Google Scholar : PubMed/NCBI
36	Nishida M, Nasu K, Ueda T, Yuge A, Takai N and Narahara H: Beta-hydroxyisovalerylshikonin induces apoptosis and G0/G1 cell-cycle arrest of endometriotic stromal cells: A preliminary in vitro study. Hum Reprod. 21:2850–2856. 2006. View Article : Google Scholar : PubMed/NCBI
37	Boroughs LK and DeBerardinis RJ: Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 17:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
38	Castro J, Ribó M, Benito A and Vilanova M: Mini-review: Nucleus-targeted ribonucleases as antitumor drugs. Curr Med Chem. 20:1225–1231. 2013. View Article : Google Scholar : PubMed/NCBI
39	Jin FP and Zhang M: Progress of experimental researches on Chinese herbal compounds for inducing tumor cell apoptosis. Chin J Integr Med. 16:565–571. 2010. View Article : Google Scholar : PubMed/NCBI
40	Zhao X, Ai M, Guo Y, Zhou X, Wang L, Li X and Yao C: Poly I: C-induced tumor cell apoptosis mediated by pattern-recognition receptors. Cancer Biother Radiopharm. 27:530–534. 2012. View Article : Google Scholar : PubMed/NCBI